共 92 条
[1]
Ferlay J(2019)Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods Int J Cancer 144 1941-1953
[2]
Colombet M(2018)De novo metastatic castration sensitive prostate cancer: State of art and future perspectives Cancer Treat Rev 70 67-74
[3]
Soerjomataram I(2017)Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice Urol Oncol 35 663.e661-663.e667
[4]
Mosillo C(2014)Prostate cancer in Asia: A collaborative report Asian J Urol 1 15-29
[5]
Iacovelli R(2015)Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer N Engl J Med 373 737-746
[6]
Ciccarese C(2019)Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or Cancer 125 1777-1788
[7]
Gaylis FD(2017)Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer N Engl J Med 377 352-360
[8]
Choi JE(2018)Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial Lancet 381 121-131
[9]
Hamilton Z(2019)Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer N Engl J Med 29 1235-1248
[10]
Chen R(2018)Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol Ann Oncol 203 751-759